{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-020968","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.092017+00:00","generated_at":"2026-06-22T12:38:43.231181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"EyePoint Q3 net product revenue $9.7M (+13% YoY); initiates two Phase 2 trials for EYP-1901; DEXYCU termination","bullets":["Q3 net product revenue $9.7M (+13% YoY); net loss $18.4M ($0.49 diluted EPS) vs $16.7M loss prior year.","Initiated Phase 2 DAVIO 2 (wet AMD) and Phase 2 PAVIA (NPDR) for EYP-1901; topline data expected Q4 2023.","Final 12-month Phase 1 DAVIO data showed positive safety: 73% reduction in treatment burden, no ocular SAEs.","DEXYCU commercialization agreement terminated effective Dec 31, 2022 due to CMS pass-through denial.","Cash $157.3M; expect to fund operations into H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-020968","json":"https://secwatch.observer/filing/0000950170-22-020968.json","markdown":"https://secwatch.observer/filing/0000950170-22-020968.md","text":"https://secwatch.observer/filing/0000950170-22-020968.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017022020968/0000950170-22-020968-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017022020968/eypt-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T12:38:43.231181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28b15c16f78d7edf13484de69362cf8cb5f99480","claim":"EyePoint, Inc. reported third quarter ended September 30, 2022 results: revenue $10.0 million, net income $18.4 million, EPS ($.49) per share.","evidence_excerpt":"For the third quarter ended September 30, 2022, total net revenue was $10.0 million compared to $9.1 million for the quarter ended September 30, 2021. Net product revenue for the third quarter was $9.7 million, compared to net product revenues for the third quarter ended September 30, 2021 of $8.6 million. Net revenue from royalties and collaborations for the third quarter ended September 30, 2022 totaled $0.3 million compared to $0.5 million in the corresponding period in 2021. Operating expenses for the third quarter ended September 30, 2022 totaled $28.4 million versus $24.4 million in the prior year period, primarily driven by investment in personnel across the organization, including non-cash stock compensation, and ongoing clinical trial and development costs for EYP-1901. Non-operating expense, net, totaled $0.02 million and net loss was $18.4 million, or ($.49) per share, compared to a net loss of $16.7 million, or ($0.58) per share, for the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017022020968/0000950170-22-020968-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$10.0 million"},{"label":"Net income","value":"$18.4 million"},{"label":"EPS","value":"($.49) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}